Core Viewpoint - The company Jianbei Miao Miao (02161) reported a strong performance in its interim results, leading to a significant increase in its stock price by over 5% [1] Financial Performance - The company reported revenue of approximately HKD 430 million for the six months ending September 30, 2025, representing a year-on-year increase of about 7.7% [1] - The profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - Earnings per share were reported at 14.12 HKD cents, with an interim dividend of 9.75 HKD cents per ordinary share [1] Business Segments - The growth in performance was primarily driven by strong sales from core brands, particularly in the branded pharmaceuticals segment with He Ji Gong and the traditional Chinese medicine segment with Bao Ji Wan [1] - The company's focus on brand management and effective market promotion execution contributed to the positive sales performance [1] - The traditional Chinese medicine formula granules business also showed stable performance, providing continuous contributions to the health business group [1]
健倍苗苗涨超5% 中期纯利同比增长约20% 派息9.75港仙